|
|
131 Varick Street, 9th floor New York, NY 10013 USA phone:212-925-0741 fax:
|
|
| Symbol |
Private |
| Founded |
2007 |
| Employees |
10 |
|
|
| www.medicasafe.com
|
|
| Research Sector |
Healthcare Services |
|
 |
| Summary Description |
| Technologies for medication compliance and adherence |
 |
| Management |
| Matt Ervin, CEO; Michael Davis, CSO; Ted Pak, CTO |
| |
|
|
| |
|
| Keywords |
| drug delivery, adherence medication compliance, patient monitoring, addictive drugs, risk management, disease management |
|
|
|
| Description |
|
MedicaSafe creates innovative technologies for medication compliance and adherence. These solutions also address needs for regular patient assessment, tracking, and medication access management, enabling creation of comprehensive treatment management systems that reduce labor and costs while improving outcomes. |
 |
| Products / Services |
MedicaSafe's products include risk management systems for 'abuse-prone' drugs and monitoring/behavioral modication systems for chronic and high-stakes medications where adherence is critical.
|
 |
| Technology / Differentiation |
| A patent-protected approach, developed with funding from the NIH, facilitates patient behavioral modification and patient tracking. The system can be geared to correct underuse of medication or, alternatively, limit drug access to prevent overuse. |
 |
| Market / Customers |
Lack of adherence/compliance in a clinical setting is estimated to produce 125,000 deaths and $100 billion in health care costs annually. MedicaSafe is targeting areas of specific applicability such as:
1) Risk Management (REMS)
2) Mental Health Medications
3) High-Value Chronic Treatments
4) Clinical Trials
|
 |
| Strategy |
Company is currently in a trial to demonstrate efficacy of their systems.
|
 |
| Funding |
| The company has funded to date primarily via NIH grants and a Series A round which includes advisory board members. |
 |
| Status |
| The company is planning a Series B financing in 2011. |
 |
|
|
|
|
|
|